{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360574093658744320.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1053/jhep.2001.25273"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2001.25273"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200107000-00021"}},{"identifier":{"@type":"NAID","@value":"30015126399"}}],"dc:title":[{"@value":"Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>The long–term effect of interferon alfa (IFN–α) in Chinese patients with chronic hepatitis B infection is unknown. A total of 411 chronic hepatitis B patients (208 treated with IFN–α and 203 as control) were followed up for hepatitis B serology and the development of hepatoma and other cirrhosis–related complications. The hepatitis B e antigen (HBeAg) seroconversion rate in the IFN–α-treated group, though significantly greater at 6 and 24 months, was comparable with the control group on subsequent follow–up, irrespective of pretreatment alanine transaminase (ALT) levels. HBeAg seroreversion rate was higher in the IFN–α group compared with the control group (21.1% vs. 2.2%; <jats:italic toggle=\"yes\">P</jats:italic> = .001). Loss of hepatitis B surface antigen (HBsAg) occurred in 2.4% of the IFN–α-treated patients and 0.49% of the control patients (<jats:italic toggle=\"yes\">P</jats:italic> = NS). Around 90% of the anti–HBe-positive patients in both groups were still hepatitis B virus (HBV)–DNA-positive by polymerase chain reaction (PCR) assay. Two patients suffered from hepatic reactivation during the course of treatment. Nine (4.3%) patients in the IFN–α group and 2 (1.0%) in the control group developed complications of cirrhosis and hepatoma (<jats:italic toggle=\"yes\">P</jats:italic> = .062). In Chinese HBsAg carriers, IFN–α was of no long–term benefit in inducing HBeAg seroconversion or in the prevention of hepatoma and other cirrhosis–related complications.</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380583646799744901","@type":"Researcher","foaf:name":[{"@value":"Man-Fung Yuen"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583646799744897","@type":"Researcher","foaf:name":[{"@value":"Chee-Kin Hui"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583646799744899","@type":"Researcher","foaf:name":[{"@value":"Chi-Chung Cheng"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583646799744900","@type":"Researcher","foaf:name":[{"@value":"Chi-Hang Wu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583646799744898","@type":"Researcher","foaf:name":[{"@value":"Yim-Ping Lai"}]},{"@id":"https://cir.nii.ac.jp/crid/1380583646799744896","@type":"Researcher","foaf:name":[{"@value":"Ching-Lung Lai"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2001-07","prism:volume":"34","prism:number":"1","prism:startingPage":"139","prism:endingPage":"145"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2001.25273"},{"@id":"https://journals.lww.com/01515467-200107000-00021"}],"createdAt":"2002-08-25","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565169376179968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Targeted Induction of Interferon-λ in Humanized Chimeric Mouse Liver Abrogates Hepatotropic Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206447135488","@type":"Article","resourceType":"other","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"7. Cutting Edge of the Treatment for Viral Hepatitis"},{"@language":"ja","@value":"7．ウイルス性肝炎の治療の進歩"},{"@value":"教育講演 ウイルス性肝炎の治療の進歩"},{"@language":"ja-Kana","@value":"キョウイク コウエン ウイルスセイ カンエン ノ チリョウ ノ シンポ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854175489556224","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Screening for hepatocellular carcinoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1053/jhep.2001.25273"},{"@type":"CIA","@value":"30015126399"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_1IulObqyFZ0POkD9fhuEwPxMkA8"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0059611_references_DOI_1IulObqyFZ0POkD9fhuEwPxMkA8"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_1IulObqyFZ0POkD9fhuEwPxMkA8"},{"@type":"CROSSREF","@value":"10.2169/naika.101.2681_references_DOI_1IulObqyFZ0POkD9fhuEwPxMkA8"}]}